Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiopulmonary exercise testing-based diagnosis and intervention study in heart failure with preserved ejection fraction
ChiCTR1800019183Phase 4Not yet recruiting
- Sponsor
- Second Hospital of Shandong University
- Start
- Dec 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of yangxinshi in heart failure with preserved ejection fraction (HFpEF) (2 arms), sponsored by Second Hospital of Shandong University. Primary endpoints: Peak oxygen uptake, Oxygen pulse and 2 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
yangxinshi
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on ChiCTR1800019183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019183.